Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic comparison of two NOMAC-E2 batches versus levonorgestrel/ethinylestradiol oral contraceptive
2009-017288-40Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nomegestrol, estradiol, avatrombopag and ethinyl estradiol in contraception (3 arms), sponsored by Merck & Co. Primary endpoint: Activated protein C resistance ratio at Cycle 3. Started Jan 2010; status: terminated.
02
Drugs
nomegestrolestradiolavatrombopagethinyl estradiol
03
Conditions
contraception
Beyond the preview
Go deeper on 2009-017288-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017288-40.